Mizuho analyst Graig Suvannavejh raised the firm’s price target on Belite Bio (BLTE) to $223 from $194 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease
- Belite Bio completes enrollment in DRAGON II trial of tinlarebant
- Netflix, Meta upgraded: Wall Street’s top analyst calls
- Belite Bio initiated with a Buy at BofA
- Belite Bio initiated with an Overweight at Morgan Stanley